Johnson & Johnson; and served as Chief Medical Officer for Atherotech Diagnostics. Robert Frederich is an employee of Bristol-Myers Squibb and holds stock in the company.

Authors\' contributions
=======================

MC and RF participated in the collection and assessment of study data included in this manuscript. Both authors helped in the drafting and revisions of this manuscript and have approved the final submitted version.

Author information
==================

MC is an adjunct professor at the University of Utah School of Medicine and is the Clinical Practice Director of Canyons Medical Center in Sandy, UT. He is a board certified Clinical Lipidologist, Fellow of the National Lipid Association (FNLA), Certified Hypertension Specialist (ASH), and member of ADA, AHA, ACC, ASA, and AAFP. RF served as medical director/monitor on 3 of the saxagliptin phase 3 trials presented inhis role at Bristol-Myers Squibb. He has previously held faculty positions at the University of Kentucky and at Harvard in the Endocrinology Division.

Acknowledgements
================

The authors wish to thank Mark Donovan, PhD, from the global biostatistics group at Bristol-Myers Squibb for his time, effort, and expertise in development of this manuscript. Technical and editorial assistance for this manuscript was provided by Diane Kwiatkoski, PhD, Paul Ruest, PhD, and Jennifer Ciafullo, MPH, Quintiles Medical Communications, Parsippany, NJ, and Erica Wehner, RPh, of Complete Healthcare Communications, Chadds Ford, PA.

Funding for this review was provided by Bristol-Myers Squibb Company and AstraZeneca Pharmaceuticals LP.
